{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.20","value":"1.57"},{"groupId":"OG001","spread":"6.14","value":"-2.81"}]}],"title":"Physical Well-Being Change from Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.08","value":"-0.03"},{"groupId":"OG001","spread":"3.53","value":"-0.23"}]}],"title":"Social/Family Well-Being Change from Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.95","value":"2.52"},{"groupId":"OG001","spread":"3.22","value":"0.60"}]}],"title":"Emotional Well-Beling Change from Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.33","value":"3.38"},{"groupId":"OG001","spread":"4.97","value":"-1.17"}]}],"title":"Functional Well-Being Change from Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.07","value":"7.44"},{"groupId":"OG001","spread":"10.92","value":"-3.61"}]}],"title":"FACT-G Change from Baseline"}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"description":"Change from baseline FACT-G scores. The quality of life questionnaire (FACT-G) was given at various timepoints during the study. The values for change from baseline to endpoint are provided.\n\nPhysical Well-Being (PWB; sum of 7 items, point range 0-28); Social/Family Well-Being (SWB, sum of 7-items, point range 0-28); Emotional Well-Being (EWB; sum of 6-items, point range 0-24); Functional Well-Being (FWB; sum of 7-items, point range 0-28) ; Fact-G score=sum of PWB, SWB, EWB, FWB, point range 0-108. Note: The higher the score, the better the outcome","dispersionType":"Standard Deviation","groups":[{"description":"Original portion of the study where patients received Revlimid® 25 mg p.o. daily on days 1-21 of each 28-day cycle. Cyclophosphamide 50 mg p.o. BID daily on days 1-21 of each 28-day cycle. Prednisone 50 mg p.o. Q.O.D.","id":"OG000","title":"Original Study - Revlimid, Cyclophosphamide, Prednisone"},{"description":"Extension portion of the study where patients received Revlimid® 25 mg p.o. daily on days 1-21 of each 28-day cycle. Cyclophosphamide 50 mg p.o. BID daily on days 1-21 of each 28-day cycle. Prednisone 50 mg p.o. Q.O.D.","id":"OG001","title":"Extension - Revlimid, Cyclophosphamide, Prednisone"}],"paramType":"MEAN","populationDescription":"All patients enrolled and received treatment with a baseline and post-baseline measurement.","reportingStatus":"POSTED","timeFrame":"baseline and after last cycle (up to 6 cycles)","title":"Quality of Life Using the FACT-G Data","type":"SECONDARY","unitOfMeasure":"scores on a scale"}